Latest Biovest Intl Inc (BVTIQ) Headlines Bio
Post# of 4
Posted On: 03/09/2014 5:03:44 AM
Latest Biovest Intl Inc (BVTIQ) Headlines
Biovest International, Inc. CEO Carlos F. Santos, Ph.D. to Present at the Phacilitate Immunotherapy Forum
Business Wire - Mon Jan 27, 6:00AM CST
Biovest International, Inc. ("Biovest"), a leader and a pioneer in the development of personalized cancer immunotherapies, today announced that Biovest's Chief Executive Officer, Carlos F. Santos, Ph.D., will deliver the keynote presentation at the Phacilitate Immunotherapy Forum (part of Phacilitate's Washington Bioleaders 2014 Conference) taking place at the Grand Hyatt Hotel on January 27-29, 2014 in Washington, D.C. The keynote presentation on Monday, January 27, 2014 is titled "The Integration of Clinical Bioinformatics, Automated Cell Culture, and Automated Manufacturing for the Rapid Development of Personalized Lymphoma Vaccines", and Dr. Santos will be a panelist for the corresponding discussion session. Dr. Santos will serve as the chair and moderator of the Tuesday, January 28, 2014 morning plenary session of the Immunotherapy Forum. He will also make a presentation titled "Case Study: Making the Personal Affordable: Efficient Manufacture of Autologous Cancer Immunotherapies", and will act as an informal panelist for the panel discussion to follow. On the final day of the Conference, January 29, 2014, Dr. Santos will present "Case Studies of Personalized Immunotherapies in Development - Examining Trial Designs and Biomarker R&D Strategies - Case Study 3".
European Medicines Agency Accepts Marketing Authorization Application for Biovest's Cancer Vaccine for Treatment of Non-Hodgkin's Follicular Lymphoma
Business Wire - Mon Jan 13, 6:00AM CST
Biovest International, Inc. ("Biovest"), a leader and pioneer in the development of personalized cancer immunotherapies, today reported that the European Medicines Agency (EMA) accepted the Company's Marketing Authorization Application (MAA) for BiovaxID(TM) (submitted to EMA as "Dasiprotimut-T Biovest"), a personalized cancer vaccine for the treatment of non-Hodgkin's follicular lymphoma. The MAA validation confirms the submission is complete and begins the formal EMA review process intended to secure approval to market BiovaxID in the European Union and to allow prescription and sale of BiovaxID for the treatment of non-Hodgkin's follicular lymphoma in patients who have achieved a first complete remission.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Accentia Biopharmaceuticals, Inc. and Certain Officers, and Biovest International, Inc. of Class Action Lawsuit and Upcoming Deadline -- ABPI and BVTIQ
GlobeNewswire - Fri Aug 30, 7:58PM CDT
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Accentia Biopharmaceuticals, Inc. ("Accentia" or the "Company") (OTC Pink:ABPI) and certain of its officers and Biovest International, Inc. ("Biovest") (OTCQB:BVTIQ), a majority-owned subsidiary of Accentia. The class action, filed in United States District Court, Middle District of Florida, and docketed under 13-CV-2033-T24-AEP, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Accentia between July 26, 2008 and August 14, 2012 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Biovest International, Inc. CEO Carlos F. Santos, Ph.D. to Present at the Phacilitate Immunotherapy Forum
Business Wire - Mon Jan 27, 6:00AM CST
Biovest International, Inc. ("Biovest"), a leader and a pioneer in the development of personalized cancer immunotherapies, today announced that Biovest's Chief Executive Officer, Carlos F. Santos, Ph.D., will deliver the keynote presentation at the Phacilitate Immunotherapy Forum (part of Phacilitate's Washington Bioleaders 2014 Conference) taking place at the Grand Hyatt Hotel on January 27-29, 2014 in Washington, D.C. The keynote presentation on Monday, January 27, 2014 is titled "The Integration of Clinical Bioinformatics, Automated Cell Culture, and Automated Manufacturing for the Rapid Development of Personalized Lymphoma Vaccines", and Dr. Santos will be a panelist for the corresponding discussion session. Dr. Santos will serve as the chair and moderator of the Tuesday, January 28, 2014 morning plenary session of the Immunotherapy Forum. He will also make a presentation titled "Case Study: Making the Personal Affordable: Efficient Manufacture of Autologous Cancer Immunotherapies", and will act as an informal panelist for the panel discussion to follow. On the final day of the Conference, January 29, 2014, Dr. Santos will present "Case Studies of Personalized Immunotherapies in Development - Examining Trial Designs and Biomarker R&D Strategies - Case Study 3".
European Medicines Agency Accepts Marketing Authorization Application for Biovest's Cancer Vaccine for Treatment of Non-Hodgkin's Follicular Lymphoma
Business Wire - Mon Jan 13, 6:00AM CST
Biovest International, Inc. ("Biovest"), a leader and pioneer in the development of personalized cancer immunotherapies, today reported that the European Medicines Agency (EMA) accepted the Company's Marketing Authorization Application (MAA) for BiovaxID(TM) (submitted to EMA as "Dasiprotimut-T Biovest"), a personalized cancer vaccine for the treatment of non-Hodgkin's follicular lymphoma. The MAA validation confirms the submission is complete and begins the formal EMA review process intended to secure approval to market BiovaxID in the European Union and to allow prescription and sale of BiovaxID for the treatment of non-Hodgkin's follicular lymphoma in patients who have achieved a first complete remission.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Accentia Biopharmaceuticals, Inc. and Certain Officers, and Biovest International, Inc. of Class Action Lawsuit and Upcoming Deadline -- ABPI and BVTIQ
GlobeNewswire - Fri Aug 30, 7:58PM CDT
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Accentia Biopharmaceuticals, Inc. ("Accentia" or the "Company") (OTC Pink:ABPI) and certain of its officers and Biovest International, Inc. ("Biovest") (OTCQB:BVTIQ), a majority-owned subsidiary of Accentia. The class action, filed in United States District Court, Middle District of Florida, and docketed under 13-CV-2033-T24-AEP, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Accentia between July 26, 2008 and August 14, 2012 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
(0)
(0)Biovest International Inc. (BVTIQ) Stock Research Links
Scroll down for more posts ▼